OBJECTIVE: Several studies have demonstrated that D-cycloserine (DCS) facilitates exposure therapy. We developed a standardized test of this facilitation (i.e., a clinical assay), with the goal of testing for facilitation more quickly and inexpensively than a full clinical trial. METHOD: We developed a standardized brief exposure in which participants with social anxiety disorder gave a videotaped speech. Participants were randomized to receive a single capsule of 250 mg DCS or a matching placebo prior to preparation for the speech. Distress levels were rated during the speech and again, approximately 1 week later, during a speech in an identical situation. Our primary measure of DCS's exposure-facilitating effect was between-session habituation: whether or not the participants showed less distress during the second speech compared to the first. We also measured levels of subjective anxiety and fear of scrutiny. RESULTS: Subjects randomized to receive DCS prior to their first speech were more likely to show between-session habituation than those who received placebo. We also found greater reduction of performance-related fear overall in the DCS group. CONCLUSION: Our clinical assay was able to detect exposure facilitation effects rapidly and in a highly standardized way, and is estimated to take a fraction of the time and costs of a clinical trial. Given the increasing interest in using medications to enhance learning-based psychotherapy, this high-throughput clinical assay approach may be a favorable method for testing novel mechanisms of action, and clarifying optimal parameters, for therapy facilitation.
RCT Entities:
OBJECTIVE: Several studies have demonstrated that D-cycloserine (DCS) facilitates exposure therapy. We developed a standardized test of this facilitation (i.e., a clinical assay), with the goal of testing for facilitation more quickly and inexpensively than a full clinical trial. METHOD: We developed a standardized brief exposure in which participants with social anxiety disorder gave a videotaped speech. Participants were randomized to receive a single capsule of 250 mg DCS or a matching placebo prior to preparation for the speech. Distress levels were rated during the speech and again, approximately 1 week later, during a speech in an identical situation. Our primary measure of DCS's exposure-facilitating effect was between-session habituation: whether or not the participants showed less distress during the second speech compared to the first. We also measured levels of subjective anxiety and fear of scrutiny. RESULTS: Subjects randomized to receive DCS prior to their first speech were more likely to show between-session habituation than those who received placebo. We also found greater reduction of performance-related fear overall in the DCS group. CONCLUSION: Our clinical assay was able to detect exposure facilitation effects rapidly and in a highly standardized way, and is estimated to take a fraction of the time and costs of a clinical trial. Given the increasing interest in using medications to enhance learning-based psychotherapy, this high-throughput clinical assay approach may be a favorable method for testing novel mechanisms of action, and clarifying optimal parameters, for therapy facilitation.
Authors: David M Clark; Anke Ehlers; Freda McManus; Ann Hackmann; Melanie Fennell; Helen Campbell; Teresa Flower; Clare Davenport; Beverley Louis Journal: J Consult Clin Psychol Date: 2003-12
Authors: Steven M Paul; Daniel S Mytelka; Christopher T Dunwiddie; Charles C Persinger; Bernard H Munos; Stacy R Lindborg; Aaron L Schacht Journal: Nat Rev Drug Discov Date: 2010-02-19 Impact factor: 84.694
Authors: Douglas S Mennin; David M Fresco; Richard G Heimberg; Franklin R Schneier; Sharon O Davies; Michael R Liebowitz Journal: J Anxiety Disord Date: 2002
Authors: Gregory S Chasson; Ulrike Buhlmann; David F Tolin; Sowmya R Rao; Hannah E Reese; Theresa Rowley; Kaitlyn S Welsh; Sabine Wilhelm Journal: Behav Res Ther Date: 2010-03-16
Authors: Mark J Millan; Yves Agid; Martin Brüne; Edward T Bullmore; Cameron S Carter; Nicola S Clayton; Richard Connor; Sabrina Davis; Bill Deakin; Robert J DeRubeis; Bruno Dubois; Mark A Geyer; Guy M Goodwin; Philip Gorwood; Thérèse M Jay; Marian Joëls; Isabelle M Mansuy; Andreas Meyer-Lindenberg; Declan Murphy; Edmund Rolls; Bernd Saletu; Michael Spedding; John Sweeney; Miles Whittington; Larry J Young Journal: Nat Rev Drug Discov Date: 2012-02-01 Impact factor: 84.694
Authors: Cheri A Levinson; Thomas L Rodebaugh; Laura Fewell; Andrea E Kass; Elizabeth N Riley; Lynn Stark; Kimberly McCallum; Eric J Lenze Journal: J Clin Psychiatry Date: 2015-06 Impact factor: 4.384
Authors: Joseph F McGuire; Monica S Wu; John Piacentini; James T McCracken; Eric A Storch Journal: J Clin Psychiatry Date: 2017-02 Impact factor: 4.384
Authors: Rasmita Ori; Taryn Amos; Hanna Bergman; Karla Soares-Weiser; Jonathan C Ipser; Dan J Stein Journal: Cochrane Database Syst Rev Date: 2015-05-10